LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

By LabMedica International staff writers
Posted on 06 Jun 2023
Print article
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels. These tests are essential in identifying type 1, type 2, and pre-diabetes, as well as managing ongoing diabetes. For diabetic individuals, monitoring HbA1c levels in the blood aids in the long-term tracking of blood glucose levels. The rising prevalence of diabetes and other lifestyle diseases is expected to drive the growth of the HbA1c testing devices market. Additionally, increased focus on preventive care and greater accuracy of HbA1c testing devices in diagnosing diabetes are expected to further contribute to market growth. However, the elevated cost of HbA1c laboratory testing may inhibit this growth. Hence, the global HbA1c testing devices market is projected to expand at a CAGR of 10.3%, from USD 1.72 billion in 2023 to USD 2.56 billion in 2027.

These are the latest findings of Research and Markets (Dublin, Ireland), a provider of market research reports and data.

The two main types of HbA1c testing devices are benchtop and handheld devices. Benchtop HbA1c testing devices, designed for ease of use on a laboratory bench, are utilized in laboratories to test patients' blood sugar levels. The advancement of HbA1c testing devices, such as point-of-care testing (POCT) and handheld devices, has simplified diabetes monitoring for both patients and healthcare professionals. These devices provide speedy and precise results, reducing reliance on conventional lab-based testing. The HbA1c testing devices market consists of automated, semi-automated, and bio-sensor-based instruments. The advent of cost-effective HbA1c tests and devices is expected to propel market growth. Various methods used to measure HbA1c include ion-exchange chromatography, electrophoretic methods, mass spectroscopy, reversed-phase HPLC, and electrospray iontophoresis, employed in hospitals, pharmaceuticals, medical devices, and laboratory testing.

The high rate of undiagnosed diabetes in emerging economies presents promising growth opportunities for the HbA1c testing devices market. Regionally, North America dominated the global HbA1c testing devices market in 2022. The growth of the HbA1c testing devices market in Europe is expected to be driven by increased product awareness and higher adoption of tests in countries such as Germany, France, and the UK. However, Asia-Pacific is projected to be the fastest-growing market for HbA1c testing devices during the forecast period, due to the evolving healthcare infrastructure in countries like China and India, as well as the rapidly rising incidence of diabetes in the region.

Related Links:
Research and Markets 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more